Sign In
Buy DCPH
$25.59
+0 (+0%)
At Close: Sep 09, 2024
Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals
01:20pm, Tuesday, 16'th Nov 2021
Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip.
DCPH Stock Alert: Why Is Deciphera Pharmaceuticals Plunging 70%?
02:42pm, Friday, 05'th Nov 2021
Today, investors in Deciphera Pharmaceuticals and DCPH stock have seen tremendous selling pressure take this stock to all-time lows. The post DCPH Stock Alert: Why Is Deciphera Pharmaceuticals Plungin
Deciphera Pharmaceuticals opened 75% down on Friday: explore why
11:02am, Friday, 05'th Nov 2021
Shares of Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) tanked 75% on Friday morning after the U.S. firm said its INTRIGUE Phase III Clinical Study failed to meet the primary endpoint. The sharp declin
Why Did Deciphera Stock Plunged 70% Today?
08:40am, Friday, 05'th Nov 2021
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in patients with gastrointestinal stromal t
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q3 2021 Results - Earnings Call Transcript
12:46am, Wednesday, 03'rd Nov 2021
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q3 2021 Results - Earnings Call Transcript
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Misses Revenue Estimates
06:24pm, Tuesday, 02'nd Nov 2021
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -6.20% and -2.14%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead f
3 Biotech Stocks With Huge Catalysts Incoming
06:13am, Friday, 22'nd Oct 2021
These drugmakers have big events that should occur before the end of 2021.
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
07:00am, Tuesday, 12'th Oct 2021
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer
Deciphera Presents New Data Across Pipeline At ESMO Congress
10:57am, Friday, 17'th Sep 2021
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced four e-poster presentations at the European Society for Medical Oncology (ESMO21) Virtual Conference 2021. The presentations include updated
Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor
08:17am, Friday, 17'th Sep 2021
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the Company will host a virtual investor event to review the rebastinib and vimseltinib clinical da
Deciphera (DCPH) Q2 Loss Wider Than Expected, Revenues Beat
10:43am, Wednesday, 04'th Aug 2021
Deciphera (DCPH) posts wider-than-expected loss in the second quarter due to rising R&D costs. Sales beat estimates on the encouraging uptake of Qinlock.
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q2 2021 Results - Earnings Call Transcript
03:25am, Wednesday, 04'th Aug 2021
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q2 2021 Results - Earnings Call Transcript
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates
06:18pm, Tuesday, 03'rd Aug 2021
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -5.22% and 5.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the
2 Beaten-Down Biotech Stocks That Could Bounce Back
06:13am, Tuesday, 27'th Jul 2021
The market hasn't been kind to these two drugmakers, but both have a chance to turn things around.
